Navigation Links
Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
Date:3/14/2013

LONDON, March 14, 2013 /PRNewswire/ --

The expiration of patents on several blockbuster drugs has been one of the major trends in the biotechnology sector in the last few years. As major pharmaceutical companies face increasing generic competition following patent expirations, they are likely to see a negative impact on their top-line. Big pharmaceutical companies have been looking to boost their product pipeline to offset the impact of the patent cliff. Another trend that could emerge as a result of this development is acquisitions. Big pharma companies may look to acquire smaller biotechnology companies that are developing potential blockbuster drugs. Companies such as Sequenom Inc. (NASDAQ: SQNM), Peregrine Pharmaceuticals (NASDAQ: PPHM), Onyx Pharmaceuticals Inc. (NASDAQ: ONXX), and Inovio Pharmaceuticals Inc. (NYSEAMEX: INO) could be among the ideal takeover targets for major pharmaceutical companies. On Wednesday, biotech stocks ended on a mixed note even as the Dow Jones posted its ninth successive higher finish. StockCall has posted free technical research reports on SQNM, PPHM, ONXX, and INO and these can be accessed by signing up at

http://www.stockcall.com/analysis

Sequenom Inc. shares posted modest gains on Wednesday, closing 0.45% higher at $4.48. The stock touched an intra-day high of $4.51, and has gained nearly 4% this week. Despite the recent gains, the biotech company's shares have fallen nearly 5% this year, even as the broad market has posted significant gains for the year. The company's shares have been struggling to break through $4.60 resistance level. The stock has just moved above its 50-day moving average, though, which is a bullish signal. The stock's MACD has also crossed above the zero-line, which further confirms the positive trend.  Download the free report on SQNM upon registration at

http://www.StockCall.com/SQNM031413.pdf  

Peregrine Pharmaceuticals shares saw a sharp decline in Wednesday's session as investors digested the company's quarterly results. The stock closed 6.33% lower at $1.48 after touching an intra-day low of $1.43. The company's shares are down more than 10% for the week. Despite the recent losses, the stock has outperformed the broad market this year. Year-to-date, Peregrine's shares have gained over 12% as compared to a jump of 9% for the S&P 500. The MACD chart for PPHM is giving bearish signal at the moment. The stock is also trading below its 50-day moving average. PPHM technical report can be accessed for free by signing up at

http://www.StockCall.com/PPHM031413.pdf  

Although Onyx Pharmaceuticals Inc. shares edged lower in trading yesterday, losses were limited. The stock ended the day 0.61% lower at $87.29 after falling to an intra-day low of $88.55. Onyx's shares are up nearly 2% for the week, despite Wednesday's pullback. The stock has had an excellent run so far this year, gaining more than 15%. The company's shares have seen a series of highs over the last few trading sessions, which is a bullish signal. The upbeat trend is confirmed by recent volume activity. The free report on ONXX can be downloaded by signing up now at

http://www.StockCall.com/ONXX031413.pdf  

Shares of Inovio Pharmaceuticals Inc. gained in the previous trading session, closing 0.43% higher at $0.540 on above average volume of 2.99 million yesterday. Inovio's shares had fallen sharply last week; however, the stock has bottomed out at around $0.525. Free report on INO can be accessed by registering at

http://www.StockCall.com/INO031413.pdf  

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

http://www.stockcall.com  


'/>"/>
SOURCE StockCall.com
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
2. Brand new Solid Form Co-Crystals and Amorphous Focus Morning at the Pharmaceutical Co-Crystals and Amorphous Material 2012 Summits
3. More than Morning Sickness: Kate Middletons Pregnancy Announcement Draws Attention to Rare Pregnancy Condition Known as Hyperemesis Gravidarum (HG)
4. Army Researcher Develops Potential Vaccine Carrier That May Give Stockpiling Efforts A Shot In The Arm
5. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
6. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
7. Southern Research Signs Agreement with Apath, LLC to Conduct Preclinical Studies with Virus-Based HCV Screenings
8. Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program
9. Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate
10. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
11. ResearchMoz: The World Anesthesia Drug Market (General, Local, Adjunctive) - Market Research Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 12, 2016  Apellis Pharmaceuticals, Inc., today ... million Series D preferred stock financing, co-led ... Capital Group and venBio Global Strategic Fund, ... IB Investment, and Epidarex Capital. The proceeds of ... advance clinical trials in the Company,s ongoing ...
(Date:2/12/2016)... February 12, 2016 ... titled Chronic Inflammation Global Clinical Trials Review, H2, ... the global clinical trials landscape along with top ... Region, Country (G7 & E7), Trial Status, Trial ... reviews top companies involved and enlists all trials ...
(Date:2/11/2016)... , Feb. 11, 2016 The primary ... and future adoption patterns on the usage of liquid ... the following: - Timeframe of liquid biopsy ... ctDNA, cfDNA and Evs—by organization type - Sample inflow ... types: blood, saliva, stool, serum, and so on. - ...
Breaking Medicine Technology:
(Date:2/12/2016)... Antonio, TX (PRWEB) , ... February 12, 2016 , ... ... love, as expressed in Blue SKies Buddha, the biography of Rama - Dr. Frederick ... fact a love story, the love of a Buddhist teacher for teaching and helping ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on Monday, February 8, ...
(Date:2/12/2016)... Middletown, PA (PRWEB) , ... February 12, 2016 , ... ... year’s event will be held in Anaheim, CA at the Anaheim Convention Center. Almost ... they can see new therapy products in action, learn more about their chosen field ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... firm announced that nominations have closed for the ISE Southeast Awards 2016. Finalists ... be announced at the ISE® Southeast Executive Forum and Awards Gala on March ...
(Date:2/12/2016)... ... 12, 2016 , ... Every winter, someone is killed, injured or loses a ... Burn Center, part of the Allegheny Health Network, has partnered with Etna Volunteer ... Heaters Need Space” campaign. , “Space Heaters Need Space” aims to bring ...
Breaking Medicine News(10 mins):